INTRODUCTION
============

Parkinson's disease (PD) is an incurable disease of aging characterized by the progressive death of dopaminergic cells in the midbrain as well as by α-synuclein-rich intracytoplasmic depositions called Lewy bodies (LBs). Treatments which alleviate disease symptoms have been available for several decades; however, these do not halt disease progression. The development of disease-modifying therapies to replace the symptomatic treatments is therefore a major priority in the biomedical research field. Genetic studies of families with a history of PD (genetic linkage studies) as well as of PD patient groups compared to matched groups of healthy individuals (genetic association studies) have identified genes and genomic variants which contribute to the development of PD ([@B24]; [@B62]). These studies have revealed at least 20 PD genes, many of which are currently the subject of studies aiming to understand their biology and disease mechanisms. For instance, several PD genes, such as parkin, DJ-1, Pten induced kinase 1 (PINK1), or ATP13A2, contribute to early onset autosomal recessive forms of Parkinsonism. Other genes are linked to Parkinsonism in an autosomal dominant fashion and are responsible for early onset forms of PD (α-synuclein duplications or triplications, some families with mutated α-synuclein) as well as the more common late onset forms of Parkinsonism (α-synuclein mutants, tau, LRRK2, VPS35, or EIF4G1; [@B34]). In this review, we focus on the dominant proteins α-synuclein, tau, and LRRK2 in light of the importance of their phosphorylation for their biological functioning.

Mutations in α-synuclein (SNCA, PARK1/4) and mutations in leucine-rich repeat kinase type 2 (LRRK2, PARK8) are linked to autosomal-dominant forms of PD ([@B24]). Also, although protein deposition of microtubule associated protein tau (MAPT) is a feature of Alzheimer's disease (AD), *MAPT* gene mutations cause frontotemporal dementia (FTD) with Parkinsonism. Interestingly, these three dominant genes in Parkinsonism (MAPT, SNCA, and LRRK2) have also been identified as risk factors for sporadic PD in genome-wide association studies (GWAS; [@B88]; [@B80]). The dominant mode of disease transmission through these genes also suggests a gain of toxic function mechanism pointing to an inhibition of toxic function as potential therapeutic strategies.

LRRK2, α-syn, and tau are all phosphorylated proteins, and their phosphorylation patterns are linked to disease ([@B48]; [@B90]). Early work showed that hyperphosphorylation of tau is correlated to pathology of tauopathies and phosphorylation of α-syn at serine129 is correlated to synucleinopathies (for reviews, see references [@B53]; [@B90]); therefore much work has focused on identifying and characterizing kinases of these proteins (for reviews, see references [@B94]; [@B55]; [@B90]). The characterization of LRRK2 phosphorylation and the link to disease is still underway although some evidence suggests that a site-dependent mixed phosphorylation state is indicative of disease. Tau and synuclein kinases have been considered as potential therapeutic targets for synucleinopathies and tauopathies and several compounds have been developed for these kinases and tested in preclinical models (for reviews on these topics, see references [@B94]; [@B40]; [@B89]). In this review, we will discuss the second main component in the regulation of protein phosphorylation of LRRK2, α-syn, and tau, namely phosphatases. We will briefly introduce the three proteins and discuss what is known about their dephosphorylation and which phosphatases and phosphatase regulators are involved. We will also discuss the relationships between the three proteins with regards to their cognate phosphatases and discuss targeting of phosphatase holoenzymes of LRRK2, α-syn, and tau as a potential phosphomodulatory therapeutic approach.

ALPHA-SYNUCLEIN
===============

The involvement of α-syn in PD was initially identified through genetic linkage studies in a small number of families ([@B69]), including mutations as well as gene duplications ([@B7]) and triplications ([@B83]). Recently, strong association was shown between α-syn and sporadic PD in GWAS ([@B79]; [@B82]). Also, α-syn is a major component of LBs ([@B86]). These arguments illustrate that α-syn is a central player in the pathogenesis of PD.

Studies investigating the phosphorylation of α-syn in diseased and aged brains have shown that α-syn can be phosphorylated at serines (S87, S129) as well as at several tyrosines including Y125, Y133, and Y136 (**Figure [1](#F1){ref-type="fig"}**). The pY125 modification has been reported to be inversely correlated with PD-related pathology. Indeed, pY125 appears to protect brains against α-syn mediated toxicity, as this modification is reduced in aged human brain tissue and absent in brain tissue affected by Lewy body dementia ([@B8]; [@B9]). The pS129 modification on the other hand is most often correlated with PD pathology. This notion is primarily supported by the finding that the majority of α-syn in LBs in postmortem PD brains is phosphorylated at S129 (pS129; [@B22]; [@B30]; [@B1]). The S129 phosphorylation of α-syn in aggregates has also been observed in animal models of PD ([@B35]; [@B63]; [@B87]). Mechanistic studies have shown that aggregated forms of α-syn are more prone to phosphorylation and that pS129 phosphorylated aggregates accumulate as the disease progresses ([@B99]; [@B57]; [@B66]; [@B100]), suggesting that the degree of α-syn pS129 phosphorylation is an indicator of disease progression.

![**Schematic of α-synuclein and its phosphorylation sites.** α-syn is a small protein of 140 amino acids in length. It is subdivided into three domains, an N-terminal alpha-helical domain, a central NAC domain (standing for non-Abeta-component) and an acidic C-terminal domain. The S129 site is hyperphosphorylated in disease and is regulated by a phosphatase of the heterotrimeric PP2A class. Please refer to **Table [1](#T1){ref-type="table"}** for an overview of studies on phosphatases regulating α-syn phosphorylation.](fgene-05-00382-g001){#F1}

The link between S129 phosphorylation and PD pathology has fueled an interest in modulating α-syn phosphorylation at S129 as a potential therapy for PD ([@B94]). Multiple kinases have been identified which phosphorylate α-syn at S129, with most evidence pointing to polo-like kinase 2 (PLK2) as the primary phosphorylated of α-syn S129 \[for an extended up to date review of α-syn phosphorylation, please refer to [@B90]\]. A straightforward therapeutic approach based on reducing α-syn phospho-S129 would be to inhibit PLK2 kinase activity; however some contradictory findings should be taken into account. For instance, overexpression of PLK2 in rat brain using adeno-associated viral vectors can suppress α-syn toxicity by promoting autophagy-mediated degradation of phospho-S129 α-syn ([@B65]). Therefore, therapies based on modulating α-syn phospho-S129 appears to require an optimal phosphorylation level rather than a complete dephosphorylation.

PHOSPHATASES OF α-SYN
=====================

Few studies have sought to identify phosphatases of α-syn ([@B5]); however, concurring data point to PP2A as a major phosphatase of the S129 site. For instance, PP2A enzyme but not PP1 is shown to dephosphorylate α-syn-pS129 *in vitro* ([@B43]), and treatment of cells with the PP2A inhibitor okadaic acid (OA) but not the PP1 inhibitor tautomycin leads to an increased level of α-syn-pS129. Further characterization showed that α-syn-pS129 was increased upon knockdown of the PP2A catalytic subunit and when PP2A enzyme is methylated.

It is important to note that the phosphatases of the PP2A class function in complexes called holoenzymes, which are composed of regulatory and catalytic phosphatase subunits. In the case of PP2A phosphatases, these are composed of a catalytic subunit (PPP2CA or PPP2CB) together with a scaffold subunit (Aα or Aβ) and a regulatory subunit (of which there are four families, B, B′, B′′, and B^′′′^, each with 2--5 different members). The precise heterotrimeric composition of the holoenzyme guides PP2A to specific substrate sites. Accordingly, the testing of four different holoenzyme compositions shows that holoenzymes with regulatory subunits of the B family are more efficient at dephosphorylating α-syn-pS129 than those of the B′ and B′′ families. Interestingly, α-syn may function in a feedback loop with PP2A, with studies reporting that α-syn has the ability to activate PP2A activity ([@B67]) and that phospho-S129 α-syn is less efficient at activating PP2A ([@B50]).

PP2A enzymes have the particularity that their enzymatic activity is positively regulated by its methylation which is itself regulated via the opposing activities of a PP2A-specific methyltransferase and a PP2A-specific methylesterase (PME). Accordingly, treatment of mice with the PME inhibitor eicosanoyl-5-hydroxytryptamide (EHT) increases PP2A methylation as well as decreased α-syn-pS129 levels in brain and a concurrent reduction in synuclein pathology ([@B43]). Related to this, the diabetes drug metformin was shown to reduce α-syn phosphorylation at S129 through activation of PP2A and inhibition of mammalian target of rapamycin (mTOR; [@B68]). These studies confirm a primordial role of PP2A in the phosphoregulation of α-syn at S129 and also provide a proof-of-principle that phosphorylation levels of α-syn can be modulated by targeting its phosphatases. Thus far, no phosphatases have been described for the tyrosine phosphorylation sites of α-syn. An overview of α-syn phosphatases is given in **Table [1](#T1){ref-type="table"}**.

###### 

Overview of studies reporting phosphatases regulating α-syn phosphorylation.

  Site   Identified phosphatase   Comments, references
  ------ ------------------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  S129   PP2A                     *In vitro* incubation with PP2A \[catalytic subunit Cα (PPP2CA), regulatory subunit Bα (PPP2R2A)\] dephosphorylates α-syn S129 better than with B′α (PPP2R5A), B′γ (PPP2R5C), or B′′ (PPP2R3A). Knockdown of PPP2CA or PPP2R2A increases α-syn S129 phosphorylation ([@B43]).
         PPP2R1A                  siRNA mediated knockdown of PPP2R1A (Protein phosphatase 2 (formerly 2A), regulatory subunit A, alpha isoform) reported to decrease α-syn S129 phosphorylation levels in neuroblastoma derived cells ([@B32]).
         PTPRA                    siRNA mediated knockdown of PPP3R1 (Protein tyrosine phosphatase, receptor type, A) reported to decrease α-syn S129 phosphorylation levels in neuroblastoma derived cells ([@B32]).
         PPP3R1                   siRNA mediated knockdown of PPP3R1 (Protein phosphatase 3 (formerly 2B), regulatory subunit B, alpha isoform) found to increase α-syn S129 phosphorylation levels in neuroblastoma derived cells ([@B32]).

See text for references to reviews discussing α-syn kinases.

LRRK2
=====

LRRK2 is a complex protein of 2527 amino acids containing several predicted functional domains (**Figure [2](#F2){ref-type="fig"}**). Several arguments underline the importance of LRRK2 for PD. First, LRRK2 is one of the most prevalent causes of monogenic PD. Furthermore, LRRK2 mutations are present in apparently sporadic cases of PD, with prevalences of 2% to up to 40% in certain population groups and LRRK2 was recently genetically associated to PD in several independent GWAS ([@B79]; [@B82]). Finally, PD patients carrying the LRRK2 mutations show a clinical and neuropathological profile which is virtually indistinguishable to sporadic PD ([@B31]), indicating that LRRK2 may contribute to a PD disease pathway common to both familial and sporadic PD.

![**Schematic of LRRK2 domain structure and currently identified LRRK2 phosphatases.** Phosphorylation sites are indicated above the LRRK2 schematic, for those sites confirmed independently by at least two different groups. Sites represented in blue indicate cellular transphosphorylation sites, in orange *in vitro* autophosphorylation sites and in green autophosphorylation sites confirmed in cells. Disease mutants are indicated below the schematic in black, mutations in italics are risk factor mutations. Arrows (for S910/S935/S955/S973/S1292) indicate the most common regulation of phosphorylation (up or down) observed across most disease mutants. Different sites are likely regulated in different ways, including through PP1 and a yet to be defined phosphatase sensitive to okadaic acid (OA). Please refer to **Table [2](#T2){ref-type="table"}** comparing the regulation of phosphorylation at S935 compared to S1292.](fgene-05-00382-g002){#F2}

LRRK2 is a highly phosphorylated protein and phosphosite mapping studies have distinguished two notable clusters of phosphorylation sites, one in or near the Ras of complex proteins (ROC) domain ([@B28]; [@B36]) and another in the interdomain region between the ankyrin repeat (ANK) and leucine rich repeat (LRR) domains (see **Figure [2](#F2){ref-type="fig"}**; [@B102]; [@B25]; [@B64]; see reference [@B48] for a detailed overview of studies reporting LRRK2 phosphorylation sites).

The physiological and pathological relevance of LRRK2 phosphorylation has only just begun to be described. For instance, phosphosites of the ANK-LRR interdomain region, including the S910/S935/S955/S973 sites, are sites phosphorylated by upstream kinases. These sites are detectable in basal conditions in multiple cellular and tissular systems, including for endogenous LRRK2 in Swiss 3T3 or NIH3T3 cells ([@B64]; [@B49]), mouse primary neurons ([@B49]), mouse brain, kidney, and lung ([@B16]; [@B11]; [@B105]; [@B14]), mouse embryonic fibroblasts ([@B21]), mouse bone marrow derived macrophages ([@B21]) and human peripheral blood mononuclear cells ([@B19]). The S910 and S935 sites mediate an interaction of LRRK2 with 14-3-3 proteins and regulate LRRK2 cellular localization ([@B64]). The search for the kinases responsible for phosphorylating LRRK2 at this cluster is still ongoing. Studies *in vitro* and in COS-7 cells have suggested a role for protein kinase A as an upstream kinase of the S910--S935 sites ([@B61]), however, these findings are not confirmed in other cell types such as HEK293T cells ([@B77]), suggesting cell-specific mechanisms of phosphorylation. This is further supported by the work of [@B21] who show that inhibitor of kappa B kinases (IKKs) phosphorylate LRRK2 in bone marrow-derived macrophages upon activation of toll-like receptor signaling which is specific to immune cells. The phosphorylation pattern of LRRK2 is completely different from that of its closest homolog LRRK1 which does not contribute to PD, suggesting that phosphorylation regulation of LRRK2 is a potential mechanism distinguishing LRRK2 from LRRK1 functionally.

Phosphorylation levels of the ANK-LRRK interdomain phosphosites are reduced for several pathogenic mutants such as R1441C/G, Y1699C, I2020T ([@B64]; [@B44]; [@B49]). This observation suggests that the reduction in LRRK2 phosphorylation levels may be involved in the pathogenic mechanism of LRRK2 PD. A corollary of that conclusion is that reduced LRRK2 phosphorylation may be used as a biomarker, however, there are some caveats. For instance, the most prevalent LRRK2 variant in patients, G2019S, does not display reduced phosphorylation levels and a recent study reported no differences in LRRK2 S935 phosphorylation in PBMCs of PD patients compared to matched healthy individuals ([@B19]). Nevertheless, the striking phosphorylation reduction at the ANK-LRR sites seen in all other confirmed LRRK2 pathogenic mutants warrants further evaluation as a disease or diagnostic biomarker.

The other major group of phosphorylation sites for LRRK2 is comprised of autophosphorylation sites. These are sites which were initially identified on LRRK2 protein after *in vitro* incubation with ATP to allow the protein to autophosphorylate itself ([@B28]; [@B36]; [@B25]). The majority of these sites cluster in the ROC domain and studies with phospho-mimicking mutants show that at least some of these modifications (T1491D, T1503D) alter LRRK2 GTP-binding properties ([@B36]; [@B101]). The precise physiological relevance of autophosphorylation sites is unknown since the majority of these sites are undetectable in cells, even on overexpressed protein. The notable exceptions are the T1410 site located in the ROC domain identified in overexpressed LRRK2 in HEK293T cells ([@B70]), the S1058 ([@B76]), and the S1292 site ([@B25]; [@B70]; [@B81]), located in the 3rd and 13th of the 14 leucine-rich repeats of the leucine-rich repeat domain, respectively, just outside the ROC domain ([@B95]). These reports suggest that at least some autophosphorylation events are occurring in cells. Specifically, the S1292 site has been characterized in more detail and displays a number of interesting features. The S1292 site is one of the few autophosphorylation sites located outside ROC. The site is phosphorylated at detectable levels in basal conditions in LRRK2 overexpressed in cell lines or in transgenic mice ([@B81]) as well as on endogenous LRRK2 in lymphocytes ([@B77]). In contrast to what is described for the ANK-LRR interdomain sites, the S1292 levels are increased in cells for the majority of pathogenic mutants and decreased in LRRK2 kinase-dead variants ([@B81]; [@B77]). Increased phosphorylation levels at S1292 may therefore be indicative of LRRK2's pathogenic state; however, this remains to be tested in PD patients. Because the kinase activating mutant G2019S shows increased phospho-S1292 and kinase dead mutants show reduced phospho-S1292, it may be suggested that phospho-S1292 levels are indicative of LRRK2 kinase activity in cells, however, some discrepancies appear. For instance, other mutants, such as N1437H, R1441C, or R1441G which are significantly less active in their kinase activity than G2019S nevertheless display similar phospho-S1292 levels relative to the G2019S ([@B81]; [@B77]). Two other pathogenic mutants, Y1699C and I2020T, which display kinase activity similar to WT or slightly increased, show varying phospho-S1292 levels depending on the system tested. Indeed, the Y1699C mutant displays increased phospho-S1292 levels in stable overexpression HEK293T cells ([@B77]) and unchanged phospho-S1292 levels in transfected HEK293T cells ([@B81]), while the inverse is true for the I2020T mutant. Further work will be required to elucidate the precise regulation of phospho-S1292 levels in LRRK2. It also remains to be shown whether the conclusions here for S1292 (an autophosphorylation site which occurs in cells) also hold true for other autophosphorylation sites or whether this is a new 'class' of sites (besides the ROC autophosphorylation cluster and the ANK-LRR interdomain cluster).

Of importance for the development of LRRK2 kinase inhibitors is that the majority of these sites is downregulated by kinase inhibitors and may therefore be used to assess inhibitor activity. For instance, the phosphorylation of autophosphorylation sites such as S1491 is inhibited by LRRK2 kinase inhibitors *in vitro* ([@B17]). Also, cellular treatment with kinase inhibitors leads to a dephosphorylation of the ANK-LRR interdomain sites S910/S935/S955/S973 ([@B20]; [@B16]; [@B17]) as well as the S1292 autophosphorylation site ([@B81]; [@B77]). Intriguingly, although the ANK-LRR interdomain phosphorylations are not autophosphorylation sites, the observed dephosphorylation of LRRK2 by kinase inhibitors can be attributed to the activity of the inhibitors on LRRK2 itself.

In sum, the emerging picture of LRRK2 phosphorylation is that LRRK2 is a highly phosphorylated protein where at least two, perhaps three, classes of phosphorylation sites can be discerned (see **Figure [2](#F2){ref-type="fig"}**). A first class of phosphosites in LRRK2 is the *in vitro* autophosphorylation site class. These sites appear after *in vitro* autophosphorylation by purified LRRK2; however, their presence in cells is not confirmed. While these sites offer opportunities to develop assays of LRRK2 kinase activity, their physiological relevance is unclear. Further work will be required to determine whether these sites occur in physiological systems under specific conditions of activation, or whether the appearance of these phosphorylations is an *in vitro* phenomenon. A second class of LRRK2 phosphorylation sites may be termed 'cellular' phosphorylation sites, including those sites of the ANK-LRR interdomain region introduced above, exemplified by the S935 site. Finally, the third and most recent class of LRRK2 phosphorylation sites is the class of cellular autophosphorylation sites, exemplified by the S1292 site, which are detected in cells and which also increase after *in vitro* autophosphorylation. The cellular sites (S935) and cellular autophosphorylation sites (S1292) are the most physiologically relevant and the comparison of both sites (summarized in **Table [2](#T2){ref-type="table"}**) suggests that these may be useful indicators of LRRK2 activity or pathology. With a few exceptions, pathogenic mutants of LRRK2 display decreased phospho-S935 levels and increased phospho-S1292 levels. It remains to be confirmed whether these changes can be used as diagnostic or disease biomarkers, either individually or together. Interestingly, cellular treatment with kinase inhibitors leads to a reduction of both S935 and S1292. Therefore, both sites are also useful as pharmacodynamic marker to assess activity of kinase inhibitors in cellular and animal models.

###### 

Comparison of the two different LRRK2 phosphorylation sites pS935 and pS1292.

  Parameter                                     pS935                                      pS1292
  --------------------------------------------- ------------------------------------------ --------------------------------------------
  Present in cells                              YES                                        YES
  Change after *in vitro* autophosphorylation   NO CHANGE                                  INCREASE
  Change after cellular kinase inhibition       DECREASE                                   DECREASE
  N1437H vs. WT                                 /                                          HIGHER
  R1441C/G vs. WT                               LOWER                                      HIGHER
  Y1699C vs. WT                                 LOWER                                      SIMILAR
  G2019S vs. WT                                 NO CHANGE                                  HIGHER
  I2020T vs. WT                                 LOWER                                      HIGHER
  G2385R vs. WT                                 LOWER                                      LOWER
  Regulation                                    IKK, PP1, +tbd                             AutoP, +tbd
  Physiological role                            14-3-3 binding, subcellular localization   Putative role in neurite length regulation

Indicated is the regulation of phosphorylation levels at these sites by autophosphorylation, cellular kinase inhibition, or disease mutants. AutoP, autophosphorylation; tbd, to be discovered.

PHOSPHATASES OF LRRK2
=====================

We recently reported that protein phosphatase 1 (PP1) is a main phosphatase of the LRRK2 ANK-LRR interdomain sites ([@B49]). The study first shows that of a panel of recombinant serine/threonine phosphatases, only protein phosphatase 1 can efficiently dephosphorylate LRRK2 *in vitro*. *In vitro* dephosphorylation was demonstrated on purified LRRK2 protein which was previously metabolically labeled by radioactive phosphates, showing that PP1 is responsible for dephosphorylation at the majority of LRRK2's phosphosites, a finding confirmed for 4 sites with phospho-specific antibodies, i.e., S910, S935, S955, and S973. Upon pharmacological inhibition of cells with either PP1 or PP2A phosphatase inhibitors, it was observed that PP1 but not PP2A inhibition could reverse LRRK2 dephosphorylation.

Interestingly, the effects of PP1 in LRRK2 phosphorylation could be confirmed in multiple cell types including HEK293T, SH-SY5Y neuroblastoma cells, mouse primary cortical neurons, U2OS osteosarcoma cells, NIH3T3 mouse fibroblast cells and A549 human lung cancer cells. This shows that PP1 is active as a LRRK2 phosphatase independent of the cell type tested, and it may be predicted that PP1 can dephosphorylate LRRK2 throughout the body.

Similar to PP2A phosphatases, PP1 class phosphatases are holoenzymes which are composed of one catalytic subunit, responsible for catalyzing the actual dephosphorylation event, and one regulatory subunit, responsible for directing the holoenzyme to its specific substrates. There are more than 150 PP1 regulatory subunits reported, allowing several 100 possible holoenzyme compositions ([@B4]). This mode of functioning is necessary given that only three PP1 catalytic subunits are expressed in mammalian cells (PP1α, PP1β, and PP1γ; HGNC codes PPP1CA, PPP1CB, and PPP1CC) which on their own are insufficiently diverse to account for the specificity in the huge volume of phosphatase activity mediated by PP1. Indeed, PP1 together with PP2A (which is represented by only two catalytic subunits, PPP2CA and PPP2CB, see below) account for more than 90% of the protein phosphatase activity in eukaryotes ([@B60]; [@B96]). This is in stark contrast to the diversity for instance of kinases, of which there are ∼400 serine/threonine kinases ([@B52]). Therefore, a key issue is to identify the composition of the PP1 holoenzyme by identifying the LRRK2-specific PP1 regulatory subunit which associates with the PP1 catalytic subunit.

There is little data available on the phosphatases involved in the regulation of LRRK2 phosphosites outside of the ANK-LRR interdomain region, however, initial evidence suggests that other phosphatases are at play. Work done at the S1292 site shows that inhibitor induced dephosphorylation of LRRK2 at S1292 is insensitive to the phosphatase inhibitors calyculin A (mixed PP1 and PP2A inhibitor) and OA (selective PP2A inhibitor; [@B77]), in contrast to what is observed at the S935 site where inhibitor induced dephosphorylation is inhibited by calyculin A ([@B49]). However, the low basal S1292 phosphorylation levels of the R1441G mutant is upregulated by both calyculin A and OA treatment ([@B77]), while the S935 phosphorylation levels of the same mutant is only upregulated by calyculin A ([@B49]). These findings suggest the hypothesis that PP2A, rather than PP1, is the phosphatase system regulating R1441G LRRK2 at S1292.

TAU
===

It may seem surprising to discuss Tau in relation to PD pathogenesis, as this protein has a relatively long history as a protein involved in neurodegenerative dementias; however, accumulating evidence puts this protein to the forefront in PD with a number of reports pointing to specific properties of Tau in PD distinguishing it from Tau in other neurodegenerative disorders. Tau is a microtubule associating protein which is involved in several neurodegenerative diseases including AD, progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and some cases of frontotemporal lobar dementia (FTLD). Although tau is mostly associated to dementias, the tau gene has also been identified as a risk factor for PD via genome wide association studies (GWAS; [@B80]). The genetic association of MAPT locus variants with PD is a striking finding, and is in stark contrast with the fact that no genetic associations of the MAPT locus are observed in AD ([@B42]), showing that tau contributes to both AD and PD but via separate mechanisms.

Tau can occur in six different splice isoforms ranging in size from 352 to 441 amino acids and at least 45 potential tau phosphorylation sites have been reported, including serine, threonine and tyrosine phosphorylation sites \[see figure schematic representation of tau protein and the localization of phosphorylation sites, **Figure [3](#F3){ref-type="fig"}**; for reviews of tau phosphorylation, please refer to [@B54],[@B55]) and [@B90]\]. Several kinases have been reported to phosphorylate tau. These include proline directed kinases \[glycogen synthase kinase 3 (GSK3), cyclin dependent kinase 5 (CDK5), and 5′ adenosine monophosphate-activated protein kinase (AMPK)\], non-proline directed kinases \[casein kinase 1 (CK1), microtubule affinity regulating kinases (MARKs), death associated protein kinase 1 (DAPK1), cyclic AMP-dependent protein kinase A (PKA) and dual specificity tyrosine-phosphorylation regulated kinase 1A (DYRK-1A)\] as well tyrosine kinases including Fyn, Abl, and Syk. The inhibition of tau phosphorylation has been proposed as a therapeutic strategy in tauopathies including early phase clinical testing of GSK-3β inhibition ([@B15]).

![**Schematic representation of the tau protein and its phosphorylation sites.** Depicted in red are mutations associated with frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17). Four main classes of phosphatases reported to regulate tau phosphorylation are given above the schematic. (Tau schematic adapted from [@B53] and [@B90]). Please refer to **Table [3](#T3){ref-type="table"}** for an overview of sites regulated by each of the four main tau phosphatase classes.](fgene-05-00382-g003){#F3}

Tau phosphorylation is important for tau function/dysfunction as hyperphosphorylation of tau is generally correlated with the formation of tau protein aggregates which are major components of neurofibrillary tangles, one of the main neuropathological hallmarks of AD which is also observed in other tauopathies including PD. Phosphorylated tau also more specifically influences its affinity for microtubules and high phosphorylation levels of tau have been reported to negatively influence cytoskeleton, synaptic functions as well as cell viability ([@B6]). Recently, some work has appeared showing some differences in the tau phosphorylation pattern in post-mortem brain of tauopathies, including PD ([@B18]). This work revealed notable differences in phosphorylation patterns between PD and other tauopathies. For instance, S202, T205, S262, S409 are hyperphosphorylated in AD and DLB, but are unchanged in PD, while others such as T181, S184, S195, S198, S237, S400 are hyperphosphorylated in all three, AD, DLB, and PD. It remains to be confirmed that these varying phosphorylation patterns are indeed related to the varying pathology observed in these different diseases.

PHOSPHATASES OF TAU
===================

In light of the importance of tau phosphorylation for its pathology, several studies have sought to identify phosphatases dephosphorylating tau (reviewed in [@B54]). These studies reveal a predominant role for PP2A, which is the most efficient phosphatase to dephosphorylate tau *in vitro* at S202, S262, and S356, but not S396 ([@B2]; [@B41]; [@B56]). This finding has been related to AD where to PP2A activity is reduced by up to 50% in AD brains ([@B97]; [@B54]), observations pointing towards the potential of targeting PP2A for therapy in tauopathies, although this relation has yet to be explored in PD. Besides the major role for PP2A, other phosphatases have also been found to act on tau phosphorylation. For instance, PP1 has been reported to act on tau at a limited number of sites in AD brains (T212, T217, S262, S396, S422; [@B74]). Similarly, PP2B (aka calcineurin) is able to dephosphorylate tau at S262 and S396 ([@B75]) while PP5 is reported to dephosphorylate tau at sites S198--S199--S202, T231--S235, S262--S356, S396--S404, and S422 ([@B26]). An overview of these four classes of phosphatases and the precise sites reported to be regulated by each is given in **Table [3](#T3){ref-type="table"}**.

###### 

Overview of different classes of phosphatases reported to regulate tau phosphorylation sites, including PP1, PP2A, PP2B, and PP5.

  Site   PP1              PP2A                             PP2B                            PP5
  ------ ---------------- -------------------------------- ------------------------------- ----------------
  S198                                                                                     [@B26]
  S199   [@B47]           [@B47]                           [@B78], [@B2], [@B47], [@B75]   [@B26], [@B47]
  S202   [@B47]           [@B47], [@B41], [@B56]           [@B78], [@B2], [@B47], [@B75]   [@B26], [@B47]
  T205   [@B47]           [@B47], [@B41], [@B56]           [@B78], [@B2], [@B47], [@B75]   [@B47]
  T212   [@B47], [@B74]   [@B47]                           [@B78], [@B2], [@B47], [@B75]   [@B47]
  S214   [@B47]           [@B47]                           [@B78], [@B2], [@B47], [@B75]   [@B47]
  T217   [@B74]                                            [@B78], [@B2], [@B75]           
  T231                    [@B78], [@B10]                                                   [@B26]
  S235   [@B47]           [@B78], [@B47], [@B10]           [@B78], [@B2], [@B47], [@B75]   [@B26], [@B47]
  S262   [@B47], [@B74]   [@B78], [@B47], [@B10], [@B56]   [@B78], [@B2], [@B47], [@B75]   [@B26], [@B47]
  S293                                                                                     
  S324                                                                                     
  S356                    [@B78], [@B10], [@B56]                                           [@B26]
  S396   [@B47], [@B74]   [@B47]                           [@B78], [@B2], [@B47], [@B75]   [@B26], [@B47]
  S404   [@B47]           [@B78], [@B47], [@B10]           [@B78], [@B2], [@B47], [@B75]   [@B26], [@B47]
  S409   [@B47]           [@B47]                           [@B78], [@B2], [@B47], [@B75]   [@B47]
  S422   [@B74]                                            [@B78], [@B2], [@B75]           [@B26]

References of reports showing activity of phosphatases per phosphorylation site mentioned in the first cell of each table row are given in the column of the corresponding phosphatase class. See text for a list of reviews discussing non-phosphatase tau phosphorylation regulators.

Thus far, the precise regulatory subunits, which may render specificity of these phosphatases to specific tau phosphosites, have yet to be elucidated and confirmed. Some evidence points to the importance of the PP2A regulatory Bα subunit in PP2A mediated phosphoregulation of tau. Expression of the Bα subunit of PP2A is decreased in frontal and temporal cortices of AD brain ([@B85], [@B84]), although it is not known if Bα subunit expression is altered in PD brain. In *in vitro* assays, the Bα subunit is found to direct the PP2A holoenzyme to microtubules ([@B103]; [@B96]), consistent with a role for the Bα subunit in the PP2A holoenzyme dephosphorylating tau.

POTENTIAL INTERPLAY BETWEEN PHOSPHORYLATION OF LRRK2, α-SYN, AND TAU
====================================================================

As LRRK2, α-syn, and tau are all three involved in dominant Parkinsonism, the hypothesis has been put forward that these three proteins interact in pathological pathways ([@B88]), most notably with synuclein and tau acting as toxic proteins and LRRK2 acting as an upstream modulator. Experimental evidence from animal models has begun to support the hypothesis of an interaction between these proteins in PD pathology. For instance, toxicity induced by high α-syn levels in mouse brain is attenuated in LRRK2 knockout mice, both in transgenic mice with high α-syn (inducible CaMKII promoter) expression levels ([@B46]) as well as after viral delivery of α-syn ([@B13]), although this has not been replicated in other transgenic mice using other promoters to drive LRRK2 and α-syn expression such as the Thy1 promoter ([@B33]) or PrP promoter ([@B12]) suggesting that the effect is dependent on expression patterns or levels. Several reports show that LRRK2 overexpression affects tau expression or tau phosphorylation (see below), supporting the hypothesis that LRRK2 modulates tau although whether LRRK2 is required for tau toxicity has yet to be tested. Interestingly, the injection of α-syn fibrillar strains into mouse brain is shown to induce tau aggregation ([@B29]), suggesting an interconnection between α-syn and tau pathological mechanisms. Studies of relationships between LRRK2, α-syn, and tau showing pairwise interactions between these proteins suggest that 3-way interaction studies, which are currently still lacking, are warranted. More information on the overall interplay between these three proteins in PD pathology can be found in recent reviews covering this topic ([@B27]; [@B90]). With regards to the topic of the present review, we highlight below the relationships between LRRK2, α-syn, and tau with regard to their phosphorylation regulation.

As LRRK2 is a kinase, it has been hypothesized that LRRK2 may phosphorylate α-syn or tau. Direct phosphorylation of α-syn by LRRK2 *in vitro* has been tested, however, this led to negative results \[reference ([@B39]) and JMT, VB unpublished results\]. Also, in LRRK2 overexpressing mice, phosphorylation levels of α-syn at S129 were found to be unchanged ([@B33]) or even reduced compared to controls ([@B46]), countering the hypothesis that LRRK2 phosphorylates α-syn. Qing and colleagues reported that crude lysates of *E. coli* expressing LRRK2 as source of enzyme could phosphorylate α-syn at S129, suggesting that LRRK2 may regulate α-syn phosphorylation in conjunction with bacterial proteins ([@B72]), although this is unlikely to be representative of a human physiological situation. The direct phosphorylation of α-syn by LRRK2 can therefore be excluded.

There is, however, evidence that LRRK2 may be involved in regulating tau phosphorylation. First, tau pathology has been observed in post-mortem brain of LRRK2 mutation carriers, including in carriers of the I1371V ([@B3]), N1437H ([@B71]), R1441C ([@B106]), Y1699C ([@B39]), G2019S ([@B45]), and I2020T ([@B93]) LRRK2 mutations. Interestingly, genetic studies suggest that tau variants influence LRRK2 disease, more specifically by influencing the age of disease onset ([@B23]), although another study found that interactions between LRRK2 and tau were at the limit of statistical significance ([@B3]). In cells and *in vivo*, several pieces of evidence point to LRRK2 in regulating tau phosphorylation. [@B51] found that overexpressed LRRK2 G2019S or I2020T in primary neurons colocalized with phospho-tau punctae in axons. Overexpression of LRRK2 via the ThyI promoter left tau and phospho-tau (S202/T205) levels unchanged in mouse brains ([@B33]), although S202 phosphorylation levels were found to be enhanced in brains of BAC transgenic mice expressing LRRK2 G2019S ([@B59]). In *Drosophila*, overexpression of LRRK2 G2019S is reported to affect tau dendritic localization and promote tau phosphorylation at T212 through the recruitment of GSK3β ([@B45]). Interestingly, LRRK2 has been shown to phosphorylate tubulin-associated tau but not free tau ([@B37]). This last finding may be related to the observations in cells that LRRK2 can in certain conditions translocate to skein-like cytoplasmic pools. Although these skein-like cytoplasmic pools have yet to be fully characterized, at least a portion of these are associated to microtubules ([@B38]). This points to a mechanism whereby LRRK2 may be recruited to microtubules where it may regulate tau phosphorylation with other kinase or phosphatase partners.

In relation to our knowledge of phosphatases of LRRK2, α-syn, and tau and the pathogenic nature of phosphorylations in these proteins, a strategy to target phosphatases in a way that will counteract PD-associated phosphorylation can be proposed. To target LRRK2 disease-related phosphorylations, PP1 would be targeted in order to modulate phosphorylation at its ANK-LRR interdomain phosphorylation sites to a 'healthy' level. For instance, pharmacological inhibition of PP1 was shown to increase the S910/S935/S955/S973 phosphorylation to levels comparable to WT. Also, PP1 inhibition was able to reduce the prevalence of LRRK2 presence in skein-like structures observed with several hypophosphorylated disease mutants ([@B49]). This effect is consistent with a reduction of microtubule associated LRRK2 and therefore reduced risk of LRRK2-mediated tau hyperphosphorylation, suggesting that PP1 inhibition may be a viable therapeutic strategy to inhibit LRRK2 mediated pathology. Thus far, the specific composition of the PP1 holoenzyme targeting the ANK-LRR interdomain sites remains to be elucidated prior to developing LRRK2-specific phosphoregulation strategies. Also, the elucidation of phosphatases regulating other sites, such as S1292, may also reveal other potential phosphatase targets for potential therapies targeting LRRK2 phosphorylation.

For α-syn, targeting PP2A holo-enzymes is a preferred strategy, more specifically through the activation of PP2A to reduce α-syn-S129 phosphorylation levels. The potential of this approach has been shown by pharmacologically enhancing PP2A activity (see above; [@B43]). The precise PP2A holoenzyme composition for α-syn-S129 has begun to be elucidated, with a preference for the B regulatory subunit above B′ and B′′ subunits. Further elucidation of the preferred C (catalytic) and A (scaffolding) subunits for α-syn-S129 will allow development of phosphatase activation by targeting the PP2A holoenzyme.

For tau, several phosphatases may be targeted, including PP2A, PP1, PP2B, or PP5. The predominant role of PP2A suggests that activation of PP2A may also be a beneficial therapeutic strategy. One issue is whether separate PP2A holoenzymes are responsible for dephosphorylation of tau at the separate phosphosites. Specifically for PD, it may be expected that dephosphorylation of tau at PD hyperphosphorylation sites should be targeted prioritarily, including T181, S184, S195, S198, S237, S400 ([@B18]). Further research will be needed to describe the PD-tau phosphorylations and their regulation.

TARGETING OF PHOSPHATASES
=========================

Modulation of phosphorylation levels of disease proteins is an attractive approach to develop disease modifying therapies. For instance, much effort has been spent on targeting kinases responsible for pathogenic phosphorylations. Kinases are also attractive drug targets. Indeed, attrition rates during development of drugs acting on kinases are lower than for most other classes of drugs ([@B98]). An important factor to bear in mind with pharmacological inhibition of kinases is that this will influence the phosphorylation levels of all of the kinase's substrates, both in the disease protein as well as for all of its other substrates. Therefore, for key phosphorylations, it may be necessary to target phosphorylations through other means than by targeting kinases. One possibility is to target phosphatases.

Phosphatases are divided into different classes, including phosphoprotein phosphatases (PPP), metal-dependent protein phosphatases and protein tyrosine phosphatases (PTP). Phosphatases from the PPP class are responsible for the vast majority of dephosphorylations of central nervous system proteins. PPPs, such as PP1 and PP2A class phosphatases, have the characteristic of functioning as a holoenzyme composed of two or more subunits, including a catalytic subunit as well as regulatory subunits. Interestingly, there are few catalytic subunits in the PPP family and the regulatory subunits have therefore generally been thought to confer substrate specificity to the holoenzyme. Emerging structural evidence is supporting this view, namely that phosphatase holoenzymes of the PPP family associate in a structured way and that this structure determines substrate specificity of the dephosphorylation. Some examples are the interaction between PP1 and spinophilin, a complex found in neurons ([@B73]), and the PP1γ--MYPT (myosin phosphatase; PPP1R12A) complex that acts as a myosin phosphatase in muscle ([@B91]; [@B104]). Based on this knowledge, it has been proposed that by targeting the holoenzyme structure, for instance by molecules which disrupt substrate-phosphatase holoenzyme complex, one can specifically modulate phosphorylation levels of proteins ([@B58]; [@B92]; see conceptual schematic in **Figure [4](#F4){ref-type="fig"}**). Based on the knowledge of the phosphatases responsible for dephosphorylation of specific phosphosites of proteins, such as emerging knowledge of the composition of phosphatase holoenzymes dephosphorylating specific sites in α-syn, LRRK2, and tau, the specific modulation of phosphorylation levels of single phosphosites is theoretically possible. Further work, including further identification and characterization of specific phosphatase holoenzyme compositions for α-syn, LRRK2, and tau and development of modulators of phosphatase holoenzyme complexes with their specific substrates, is required to test the efficacy of this approach.

![**Regulation of protein phosphorylation via modulators of phosphatase holoenzymes.** Several phosphatase classes, such as PP1 and PP2A class phosphatases depicted here function as multiprotein holoenzymes including a catalytic subunit and regulatory subunits. Phosphatase activity can be modulated by protein-protein interaction modulators (depicted here as red studded bars) which can either disrupt the holoenzyme complex itself or disrupt binding of the holoenzyme to its substrate.](fgene-05-00382-g004){#F4}

CONCLUSION
==========

The three main proteins linked to Parkinsonism, α-syn, tau, and LRRK2 all display phosphorylations which are modified in disease. The phosphorylation changes are the result of a balance between activity of kinases and phosphatases. Emerging evidence points to phosphatases regulating different pathological phosphorylations in these three proteins, primarily PP1 for LRRK2 and PP2A for α-syn and tau. It appears now feasible to target phosphatases of α-syn, tau, and LRRK2 in order to alleviate pathology mediated by pathological phosphorylation of these disease proteins. In order for this approach to reach its full potential, additional research will be required further linking individual or clustered phosphorylation events in these three proteins to disease. Also, refined knowledge of the precise holoenzyme compositions for each pathological phosphorylation is necessary to develop highly specific phosphatase holoenzyme modulators.
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